Share this Article
Akere A, Otegbayo JA
Correspondence: Dr Jesse Abiodun Otegbayo, firstname.lastname@example.org
Introduction The p53 antigen is oncoprotective and when damaged, leads to production of anti-p53. It also predisposes to various cancers, including hepatocellular carcinoma (HCC). Serum anti-p53 has been proven to have prognostic and other values in patients with HCC. The objectives of this study were to determine the serum pattern, prevalence, diagnostic and prognostic utility of serum anti-p53 in Nigerians with HCC.
Methods 41 subjects with HCC and 45 apparently-healthy controls were matched for age and sex. Serum anti-p53 was determined using p53-autoantibody ELISA kit.
Results The mean age of the patients was 48.9 (+/- 13.8) years, and that of controls was 49.4 (+/- 13.7) years. There was male predominance among the patients, 31 men (75.6 percent) versus ten women (24.4 percent), with a male-to-female ratio of 3.1:1. Similar values among controls were 33 men (73.3 percent) versus 12 women (26.7 percent), with a male-to-female ratio of 2.75:1. Anti-p53 was detectable in the sera of five (12.2 percent) patients and four (8.9 percent) of controls (p-value is greater than 0.05). All the patients with positive sera were males, while one of the controls was a female. Three (60 percent) of the positive patients were in the age range 40-49 years, while in the control group, they were in the age range 50-59 years.
Conclusion There is a low prevalence of serum anti-p53 in our study population, and this is commoner in men. It is also present in the control group and therefore may not be useful as a diagnostic tool in this study population.
Keywords: anti-p53, hepatocellular carcinoma, serum anti-p53
Singapore Med J 2007; 48(1): 41–44